Improvement Of Glycemic Control Through Beta-Cell Administration Of Mir192

Technology Description

Improvement of glycemic control through beta-cell administration of Mir192. Despite the clinical benefits of GLP1R agonists, adverse effects such as gastrointestinal symptoms (nausea, diarrhea, and vomiting) significantly limit drug tolerability in some individuals. These have been attributed to GLP1R activation in the hypothalmus. Thus, development of a novel therapeutic that can specifically upregulate b-cell GLP1R levels could significantly amplify the efficacy of GLP1R agonists, enabling use of lower, more tolerable, doses without impacting efficacy for glycemic maintenance in patients with diabetes who have impaired (but not absent) b-cell function.

Stage of Development

proof of concept

Related Materials

• MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion - 03/19/2025

Patent Status

Patent Pending